Ozurdex Monotherapy Trial

NCT05101928 · clinicaltrials.gov ↗

PHASE4

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped The study was withdrawn due to insufficient participant enrollment.

Conditions

Uveitis, Posterior
Uveitis, Intermediate
Panuveitis

Interventions

DRUG: Ozurdex 0.7mg Ophthalmic Implant
DRUG: Prednisone

Sponsor

Ottawa Hospital Research Institute